deltatrials
Recruiting PHASE1 Interventional 2-arm NCT03809208

Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

A Phase I Study of Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: National Cancer Institute (NCI)

Conditions Facial Cancer Head Cancer Neck Cancer Oral Cancer Upper AerodigestiveTract Cancer
Interventions Birinapant Intensity modulated re-irradiation therapy (IMMRT)
Updated 3 times since 2019 Last updated: Mar 28, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Facial Cancer and Head Cancer and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshotNot Yet Recruiting~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshotNot Yet Recruiting~Apr 2019 – present · 87 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Apr 2019 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE1

  3. Feb 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations